Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.
2.

Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.

3.

Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.

Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI.

Breast Cancer Res Treat. 2006 Mar;96(2):131-46. Epub 2005 Oct 27.

PMID:
16261397
4.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

5.

Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.

Ram PT, Kiefer T, Silverman M, Song Y, Brown GM, Hill SM.

Mol Cell Endocrinol. 1998 Jun 25;141(1-2):53-64.

PMID:
9723886
6.

[Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].

Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.

Ai Zheng. 2006 Jul;25(7):839-43. Chinese.

PMID:
16831274
7.

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.

Breast Cancer Res Treat. 2010 Jan;119(2):283-93. doi: 10.1007/s10549-009-0345-x. Epub 2009 Feb 24.

PMID:
19238537
8.

Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S75-84.

9.

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Review.

10.
11.

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI.

Breast Cancer Res. 2008;10(6):R103. doi: 10.1186/bcr2206. Epub 2008 Dec 4.

12.

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.

Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD.

Breast Cancer Res Treat. 2011 Jun;127(2):375-84. doi: 10.1007/s10549-010-1004-y. Epub 2010 Jul 3.

PMID:
20602165
13.

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M.

J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41.

PMID:
12361723
14.

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Review.

15.

Mechanism of estrogen-induced apoptosis in breast cancer cells: role of the NF-kappaB signaling pathway.

Lobanova YS, Scherbakov AM, Shatskaya VA, Krasil'nikov MA.

Biochemistry (Mosc). 2007 Mar;72(3):320-7.

PMID:
17447886
16.

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.

Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.

Breast Cancer Res. 2008;10(6):R104. doi: 10.1186/bcr2208. Epub 2008 Dec 5.

17.

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M.

J Biol Chem. 2003 Aug 15;278(33):30458-68. Epub 2003 May 29.

18.

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.

Massarweh S, Schiff R.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. Review.

19.
20.
Items per page

Supplemental Content

Write to the Help Desk